RECRUITINGINTERVENTIONAL

Snus and Home Blood Pressure

The Effects of Snus on Home Blood Pressure and Metabolism

About This Trial

Snus is a type of snuff that is administered sublabially, that has not been studied regarding the effects on home blood pressure and metabolism on a longer time frame. The primary aim of this study is to evaluate the effect of snus on home BP within weeks to months in former snus users who continue to not use snus or relapse in daily snus use, respectively. The secondary aim is to evaluate the effects on metabolic measurements. The hypothesis is that BP will increase amongst the participants that resume snus intake. 28 healthy volunteers with a pre-existing daily use of snus will be recruited and followed during snus cessation. Home blood pressure, lipid and metabolic markers will be measured before and after snus cessation, as well as after snus relapse if such a relapse occurs.

Who May Be Eligible (Plain English)

Who May Qualify: - daily use (defined as at least once daily for at least 1 month) o snus - the ability to use online questionnaires written and answered in Swedish Who Should NOT Join This Trial: - simultaneous use of any other nicotine or tobacco product (including cigarette smoking, e-cigarettes, and nicotine replacement therapy) - drug use (including cannabis) - alcohol dependence - known cardiovascular disease (including hypertension, previous myocardial infarction, stroke, peripheral arterial disease, or angina pectoris), kidney disease, hormonal disease (including diabetes mellitus) or eating disorder - current or planned pregnancy. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * daily use (defined as at least once daily for at least 1 month) o snus * the ability to use online questionnaires written and answered in Swedish Exclusion Criteria: * simultaneous use of any other nicotine or tobacco product (including cigarette smoking, e-cigarettes, and nicotine replacement therapy) * drug use (including cannabis) * alcohol dependence * known cardiovascular disease (including hypertension, previous myocardial infarction, stroke, peripheral arterial disease, or angina pectoris), kidney disease, hormonal disease (including diabetes mellitus) or eating disorder * current or planned pregnancy.

Treatments Being Tested

OTHER

Snus with or without tobacco

At baseline, participants have used the intervention daily for at least 30 days. They will then cease usage of the intervention abruptly. After 3 weeks, they may continue to abstain from the intervention or relapse at their own discretion.

Locations (1)

Primary Health Care Center Cityhälsan Centrum

Norrköping, Sweden